Differences and price comparison between imported and domestic versions of Regorafenib

Regorafenib is a multi-target tyrosine kinase inhibitor that is widely used in the treatment of various malignant tumors such as advanced colorectal cancer, gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma. As the drug gradually becomes popular in domestic and foreign markets, patients are particularly concerned about the differences and price comparisons between its imported and domestic versions. The following will be analyzed from the perspectives of version differences, price differences, medical insurance policies and patient selection.

First of all, from the perspective of drug version, regorafenib has been successfully launched in China by Bayer’s original drug, and has gradually been included in the national medical insurance catalog. This means that domestic patients can purchase Bayer’s original drugs in regular hospital pharmacies, while reducing their financial burden through medical insurance reimbursement. In recent years, some domestic manufacturers have been developing or imitating alternative drugs to regorafenib and gradually putting them on the market. The domestic version of regorafenib is consistent with the original drug in terms of drug ingredients and mechanism of action, but there are certain gaps in production technology, brand recognition and market pricing. As a result, patients often weigh a drug's provenance and clinical trust when making a choice.

Secondly, from a price perspective, the price difference of regorafenib is relatively obvious. The price of original research drugs on the domestic market is about RMB 4,000 to 5,000, and the patient's out-of-pocket portion will be further reduced after medical insurance reimbursement. The domestic version is more affordable and can be obtained for only a few hundred yuan, so it has obvious advantages for patients with heavy financial burdens. In the international market, the Turkish version of the original drug is relatively cheap, with a price of about more than 1,000 yuan. At the same time, the price of generic drugs from countries such as Laos, India and Bangladesh ranges from a few hundred yuan to more than a thousand yuan, which is significantly lower than that of domestic original drugs. This makes overseas generic drugs an important choice for many patients when seeking alternative treatments.

Thirdly, from the perspective of medical insurance and accessibility, since domestic original drugs have been included in the medical insurance catalog, patients can be reimbursed with regular hospital prescriptions, and the overall expenditure will be significantly reduced. This is also one of the important reasons why domestic patients tend to choose original drugs. Although the domestic version is low in price, it may not be fully included in the medical insurance system in some areas, and patients need to purchase it at their own expense. As for overseas versions, whether they are original research or generic drugs, although they are cheaper, since they involve cross-border drug purchases, channel compliance and quality assurance are issues that patients must pay attention to. It is generally recommended that patients obtain drugs through regular overseas medical institutions or legal channels to avoid the risk of counterfeit or inferior drugs.

Finally, from the perspective of patients’ actual needs, regorafenib treatment often requires long-term medication, so the balance between price and efficacy is crucial. For patients covered by medical insurance, choosing domestic original drugs not only guarantees quality, but also provides medical insurance support, making the overall drug use more economical. For patients who cannot be reimbursed or are under great financial pressure, domestic versions and overseas generic drugs may become more realistic options. In general, regorafenib has formed a pattern of coexistence of original drugs and generic drugs in domestic and foreign markets. The price gap is large, and patients can choose reasonably according to their own economic situation and treatment needs.

Reference link:https://www.drugs.com